Alnylam has a license to use our IP to develop and commercialize products and may only grant access to our LNP technology to its partners if it is part of a product sublicense. Alnylam’s license rights are limited to patents that we have filed, or that claim priority to a patent that was filed, before April 15, 2010. Alnylam does not have rights to our patents filed after April 15, 2010 unless they claim priority to a patent filed before that date. Alnylam will pay us low single digit royalties as Alnylam’s LNP-enabled products are commercialized.
In September 2017 Alnylam announced that its APOLLO Phase 3 study of patisiran, an RNAi therapeutic developed for patients with hereditary ATTR amyloidosis with polyneuropathy (FAP), met its primary efficacy endpoint and all secondary endpoints. In August 2018, the FDA approved Alnylam’s ONPATTRO for treatment of ATTR amyloidosis patients with FAP.
Topline results from this study demonstrated that patisiran met its primary efficacy endpoint and all secondary endpoints. This program represents the most clinically advanced application of our LNP delivery technology. We are entitled to single-digit royalty payments escalating based on sales performance as Alnylam’s LNP-enabled products are commercialized.